Pneumococcal Vaccine for Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices, United States, 2023
Abstract
This report compiles and summarizes all published recommendations from cdc’s advisory committee on immunization practices (acip) for use of pneumococcal vaccines in adults aged ≥19 years in the united states. this report also includes updated and new clinical guidance for implementation from cdc:
Before 2021, acip recommended 23-valent pneumococcal polysaccharide vaccine (ppsv23) alone (up to 2 doses), or both a single dose of 13-valent pneumococcal conjugate vaccine (pcv13) in combination with 1–3 doses of ppsv23 in series (pcv13 followed by ppsv23), for use in u.s. adults depending on age and underlying risk for pneumococcal disease. in 2021, two new pneumococcal conjugate vaccines (pcvs), a 15-valent and a 20-valent pcv (pcv15 and pcv20), were licensed for use in u.s. adults aged ≥18 years by the food and drug administration:
Acip recommendations specify the use of either pcv20 alone or pcv15 in series with ppsv23 for all adults aged ≥65 years and for adults aged 19–64 years with certain underlying medical conditions or other risk factors who have not received a pcv or whose vaccination history is unknown. in addition, acip recommends use of either a single dose of pcv20 or ≥1 dose of ppsv23 for adults who have started their pneumococcal vaccine series with pcv13 but have not received all recommended ppsv23 doses. shared clinical decision-making is recommended regarding use of a supplemental pcv20 dose for adults aged ≥65 years who have completed their recommended vaccine…
Read the paper
Related studies
- Association of lower urinary tract symptoms and OAB severity with quality of life and mental health in China, Taiwan and South Korea: results from a cross-sectional, population-based study
- Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China
- The Role of the NLR and PLR in Urinary Tract Infection
- Threat of Antimicrobial Resistance among Pilgrims with Infectious Diseases during Hajj: Lessons Learnt from COVID-19 Pandemic
- Leclercia adecarboxylata urinary tract infection in a patient with bladder cancer and recurrent hematuria
- A Case Series of Staphylococcus lugdunensis Infection in Cancer Patients at an Academic Cancer Institute in the United States
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.